Background. Plazomicin is a next generation aminoglycoside that is not affected by most commonly-encountered aminoglycoside modifying enzymes and is currently being studied in a global Phase 3 trial enrolling patients with bloodstream infections or nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae. The activity of this novel agent was tested against a contemporary collection of Enterobacteriaceae from New York City.
Methods. Unique patient isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. were gathered from 11 hospital microbiology laboratories from November 2013 through January 2014. Isolates underwent susceptibility testing by the agar dilution method according to CLSI guidelines. Cephalosporin-resistant isolates were screened for the presence of bla KPC .
Results. A total of 2866 isolates of E. coli (two with bla KPC ), 944 isolates of K. pneumoniae (125 with bla KPC ), and 216 isolates of Enterobacter spp. (7 with bla KPC ) were collected. Susceptibility results for gentamicin, amikacin, and plazomicin are shown in the 
